Clearfield (NASDAQ:CLFD) reported quarterly earnings of $1.22 per share which beat the analyst consensus estimate of $0.86 by 41.86 percent. This is a 130.19 percent increase over earnings of $0.53 per share from the same period last year. The company reported quarterly sales of $95.00 million which beat the analyst consensus estimate of $71.42 million by 33.02 percent. This is a 110.01 percent increase over sales of $45.24 million the same period last year.
Regeneron Says FDA Approves Dupixent (dupilumab) As First Biologic Medicine For Children Aged 6 Months To 5 Years With Moderate-To-Severe Atopic Dermatitis
FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis
Children treated with Dupixent and topical corticosteroids (TCS) achieved
